Psilocybin for migraine disorders

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 2 registered trials.

Why this status

  1. 6 Jan 2020: Trial registered, NCT04218539
  2. 10 Aug 2021: Trial started, NCT04218539
  3. 18 Jun 2024: Trial registered, NCT06464367
  4. 19 May 2025: Trial started, NCT06464367

The trials

NCT04218539: Repeat Dosing of Psilocybin in Migraine Headache

State
Completed
Phase
Phase 1
People
18 taking part
Started
10 Aug 2021
Primary completion
5 Nov 2023
Arms
Psilocybin/Psilocybin
Results
None posted
  1. 6 Jan 2020: Trial registered
  2. 10 Aug 2021: Trial started
  3. 5 Nov 2023: Trial completed

NCT06464367: Mechanistic Studies of Psilocybin in Headache Disorders

State
Under way
Phase
Early Phase 1
People
50 planned
Started
19 May 2025
Primary completion
31 Dec 2027
Arms
Migraine psilocybin, Healthy control psilocybin
Results
None posted
  1. 18 Jun 2024: Trial registered
  2. 19 May 2025: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 1 trial

About the treatment

Also known as High Dose Psilocybin, Low Dose Psilocybin, Medium Dose Psilocybin, Psilocybin (0.25mg/kg), Psilocybin (Usona Institute), Psilocybin (drug), Psilocybin 100 mcg/kg, Psilocybin 25 mg, Psilocybin 25 mg per os, Psilocybin 25mg, Psilocybin assisted therapy, Psilocybin first, Psilocybin plus Visual Healing Set and Setting, Psilocybin therapy, psilocybin 25 mg sod.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.